WallStreetZenWallStreetZen

NASDAQ: TLSA
Tiziana Life Sciences Ltd Stock

$0.84+0.01 (+1.2%)
Updated Mar 24, 2023
TLSA Price
$0.84
Fair Value Price
$1.11
Market Cap
$85.91M
52 Week Low
$0.50
52 Week High
$1.15
P/E
-3.5x
P/B
2.08x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$23.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$22M
Beta
0.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TLSA Overview

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TLSA ($0.84) is undervalued by 24.51% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TLSA ($0.84) is significantly undervalued by 24.51% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TLSA due diligence checks available for Premium users.

Be the first to know about important TLSA news, forecast changes, insider trades & much more!

TLSA News

Valuation

TLSA fair value

Fair Value of TLSA stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
$1.11
Undervalued by
24.51%
TLSA ($0.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TLSA ($0.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TLSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TLSA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.5x
Industry
17.88x
Market
21.37x

TLSA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.08x
Industry
4.89x
TLSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TLSA's financial health

Profit margin

Revenue
$0.0
Net Income
-$23.4M
Profit Margin
0%
TLSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$48.8M
Liabilities
$7.5M
Debt to equity
0.18
TLSA's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLSA's short-term assets ($48.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLSA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$21.8M
Investing
$130.0k
Financing
-$23.0k
TLSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TLSA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TLSA$85.91M+1.82%-3.50x2.08x
HOWL$85.73M+11.98%-1.31x0.70x
ORMP$85.54M-0.92%-2.29x0.56x
CELU$85.41M-1.67%1.47x0.52x
DARE$86.52M0.00%-2.83x3.28x

Tiziana Life Sciences Stock FAQ

What is Tiziana Life Sciences's quote symbol?

NASDAQ: TLSA) Tiziana Life Sciences trades on the NASDAQ under the ticker symbol TLSA. Tiziana Life Sciences stock quotes can also be displayed as NASDAQ: TLSA.

If you're new to stock investing, here's how to buy Tiziana Life Sciences stock.

What is the 52 week high and low for Tiziana Life Sciences (NASDAQ: TLSA)?

(NASDAQ: TLSA) Tiziana Life Sciences's 52-week high was $1.15, and its 52-week low was $0.50. It is currently -26.96% from its 52-week high and 68% from its 52-week low.

How much is Tiziana Life Sciences stock worth today?

(NASDAQ: TLSA) Tiziana Life Sciences currently has 102,272,614 outstanding shares. With Tiziana Life Sciences stock trading at $0.84 per share, the total value of Tiziana Life Sciences stock (market capitalization) is $85.91M.

Tiziana Life Sciences stock was originally listed at a price of $1.67 in Nov 20, 2018. If you had invested in Tiziana Life Sciences stock at $1.67, your return over the last 4 years would have been -49.7%, for an annualized return of -15.78% (not including any dividends or dividend reinvestments).

How much is Tiziana Life Sciences's stock price per share?

(NASDAQ: TLSA) Tiziana Life Sciences stock price per share is $0.84 today (as of Mar 24, 2023).

What is Tiziana Life Sciences's Market Cap?

(NASDAQ: TLSA) Tiziana Life Sciences's market cap is $85.91M, as of Mar 27, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tiziana Life Sciences's market cap is calculated by multiplying TLSA's current stock price of $0.84 by TLSA's total outstanding shares of 102,272,614.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.